It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Advances deployment of mRNA technology across vaccines and therapeutics development
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
It works as an adjunct to standard care based on robust clinical trials
Turnover of API division of ISLL stood at Rs 856.58 crore
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
